OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Shares Shorted: Short Interest Down 40.5% in October

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO – Get Free Report) was the target of a significant drop in short interest in October. As of October 30th, there was short interest totaling 45,609 shares, a drop of 40.5% from the October 15th total of 76,652 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily volume of 54,910 shares, the days-to-cover ratio is currently 0.8 days.

OKYO Pharma Stock Down 6.0%

Shares of NASDAQ:OKYO opened at $1.10 on Wednesday. The stock’s 50-day moving average price is $1.39 and its 200-day moving average price is $1.57. OKYO Pharma has a 12-month low of $1.10 and a 12-month high of $3.20.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Weiss Ratings lowered OKYO Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday. HC Wainwright reiterated a “buy” rating on shares of OKYO Pharma in a research report on Wednesday, October 7th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $5.67.

Get Our Latest Report on OKYO

Institutional Investors Weigh In On OKYO Pharma

An institutional investor recently bought a new position in OKYO Pharma stock. Opaleye Management Inc. purchased a new position in shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO – Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 375,204 shares of the company’s stock, valued at approximately $563,000. Opaleye Management Inc. owned about 0.71% of OKYO Pharma at the end of the most recent reporting period. Institutional investors and hedge funds own 2.97% of the company’s stock.

OKYO Pharma Company Profile

(Get Free Report)

OKYO Pharma Limited is a clinical-stage biopharmaceutical company developing treatments for inflammatory eye diseases and ocular pain. Its research focuses on therapies intended to reduce inflammation and improve symptoms affecting the eye. The company’s lead candidate, urcosimod (OK-101), is a topical eye-drop treatment being developed for dry eye disease. It is designed to act on ChemR23, a receptor involved in regulating inflammation. OKYO has also investigated the candidate’s potential for treating neuropathic corneal pain.

See Also

Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.